NEUROCRINE BIOSCNCE (NB3 MU) stock market data APIs
€121.7176
1.18(1%)
as of September 25, 2026
Try our APIs with
free plan!
NEUROCRINE BIOSCNCE Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for NB3.MU.
Prev. Close
121.7176
Open
122.895
High
123.9254
Low
120.303
52 wk Range
104.55-160.4
Market Cap
6 691 M
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get NEUROCRINE BIOSCNCE data using free add-ons & libraries
Get NEUROCRINE BIOSCNCE Fundamental Data
NEUROCRINE BIOSCNCE Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
NEUROCRINE BIOSCNCE News
New
Neurocrine’s (NBIX) Data Deluge Reshapes A Familiar Growth Story
On August 12, Neurocrine Biosciences (NASDAQ:NBIX) published something unusual for a psychiatric drug: proof that patients feel the difference, not just that a clinician's scale says they moved less. ...
Neurocrine Biosciences' Ingrezza, Crenessity to Drive H2 Ahead of 'Catalyst-Rich' 2027, RBC Says
Neurocrine Biosciences' (NBIX) Ingrezza and Crenessity products are expected to drive H2 appreciatio PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Neurocrine Biosciences to Present at Upcoming Investor Conferences in September
SAN DIEGO, Sept. 2, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its executives will participate at the following investor conferences: Wells Fargo 21st Annua...
Neurocrine's Crenessity Gains Ground in CAH: How Far Can Sales Go?
Neurocrine Biosciences NBIX continues to rely heavily on its blockbuster VMAT2 inhibitor, Ingrezza, for top-line growth. Still, the company is making meaningful progress beyond the drug as Crenessity ...
Get NEUROCRINE BIOSCNCE fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
